ABSTRACT
The industry has responded by incorporating remote monitoring techniques and fast-tracking the use of hybrid and decentralized clinical trial (DCT) models, at a pace never seen before. Interactive voice response systems (IVRS) and electronic data capture (EDC) solutions were introduced in the late 1980s and early '90s but these are only now reaching wide adoption by sponsors and contract research organizations (CROs).1 Electronic patient-reported outcomes (ePRO), electronic clinical outcomes assessment (eCOA), and eSource technologies, while introduced in the mid to late '90s, have yet to achieve wide adoption.2 This pattern holds true for risk-based monitoring (RBM), digital health outcomes, and other innovative approaches and solutions. [...]the survey focused on opportunities for accelerating the innovation adoption process. A variety of roles were also represented, including professionals from clinical operations (46%);clinical development (9%);innovation management (17%);data science & data management (10%);information technology (3%);and 15% from other roles. [...]14.5% of respondents were part of a centralized or dedicated innovation group, whereas the majority (85.5%) worked outside of such an innovation group. [...]responses reflect a broad cross-section of views and perspectives from which to learn more about how the biopharmaceutical industry approaches the innovation adoption process, what gets in the way, and how organizations and the industry more broadly can accelerate new technologies and innovations.